Nanobody treatment to block MSUT2 and reduce harmful tau in Alzheimer's
Official title: Developing MSUT2 Nanobodies for Targeting Pathological Tau in Alzheimer's Disease
Funded at VA Puget Sound Healthcare System · NIH-11264893 · Data updated 2026-11-12
Tiny antibody-like treatments called nanobodies will be developed to block a protein (MSUT2) that helps harmful tau damage brain cells in people with Alzheimer's disease.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | VA Puget Sound Healthcare System NIH-funded |
| Lab location | 1 site (Seattle, United States) |
| Project start | January 1, 2022 |
| Project end | December 31, 2026 |
| Funding year | 2026 |
| NIH project number | 5I01BX005742-05 |
| Project ID | NIH-11264893 on NIH RePORTER |
Who could benefit from this research
✓Could help
Adults with Alzheimer's disease or related tauopathies, especially those with evidence of tau accumulation and in early-to-moderate stages, would be the likely candidates for future trials.
✕Less likely to help
People whose dementia is caused by non-tau diseases or who have very advanced, widespread brain damage may not benefit from this approach.
What this research studies
Researchers are making small, brain-penetrant antibody-like proteins (nanobodies) that stop MSUT2 from binding RNA, because MSUT2 activity makes neurons more vulnerable to tau-related damage. They will optimize these nanobodies and delivery methods and test them in laboratory and animal models that mimic human Alzheimer's to see if blocking MSUT2 can reverse tau-driven neurodegeneration after it starts. The team will use these tools to learn when and how MSUT2 makes tau more toxic and to produce lead biologic agents for future translation. The work is based at VA Puget Sound and is intended to set the stage for later human testing if results are promising.
Why it matters
Potential benefit: If successful, this could lead to new treatments that reduce tau-related brain damage and slow memory and thinking decline in people with Alzheimer's.
How similar studies have gone: Existing antibody and gene approaches targeting tau have had mixed outcomes, and targeting MSUT2 with nanobodies is a novel approach not yet tested in people.
Where this research is happening
-
VA Puget Sound Healthcare System
Seattle, United States Active
Researchers
- Principal investigator: Kraemer, Brian C. — VA Puget Sound Healthcare System
- Study coordinator: Kraemer, Brian C.
Related research
Other NIH-funded projects on the same topics.
-
Understanding how brain activity changes may drive Alzheimer’s disease progression in a mouse model
Researchers are testing how changes in brain signals and protein cleanup processes affect the development of Alzheimer’s disease in mice.
-
Thiamine-boosting therapy for Alzheimer’s: understanding how benfotiamine may reduce harmful AGE in DP patients
A medication-based approach using high-dose vitamin B1 (benfotiamine) is studied to help people with Alzheimer's by reducing harmful sugar-related molecules.
-
Non-invasive tears biomarker for early Alzheimer's in LMICs
A low-cost, tear-based biomarker approach aims to detect early Alzheimer’s disease in older adults in Peru and similar settings.
-
Turning APOE4 into protective APOE2 or APOE3Christchurch to help with Alzheimer’s
A patient-facing explanation of a treatment idea that aims to change a genetic risk factor for Alzheimer's disease in the brain.
-
Telomerase in Alzheimer’s Disease: how aging biology could influence memory and brain health
Researchers are exploring a new brain-aging mechanism linked to telomerase, with potential to slow or modify Alzheimer’s disease in people and improve cognitive function.
-
Biomarkers of Alzheimer’s Disease: Sensory, Motor, and Cognitive Clues
Researchers are testing simple sensory and movement tasks to find early signs of Alzheimer’s disease so they can diagnose and treat people sooner.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.